Venlafaxine
Venlafaxine is an SNRI antidepressant used off-label for menopausal hot flashes, with among the best evidence among non-hormonal options and a fast onset.
How it works
Venlafaxine inhibits reuptake of both serotonin and norepinephrine. In the context of hot flashes, serotonin signaling in the hypothalamus plays a role in thermoregulation — reduced central serotonin is thought to contribute to the dysregulation that causes hot flashes after estrogen decline. By increasing serotonin availability, venlafaxine partially restores that regulatory stability. Trials typically show 50–60% reduction in hot flash frequency, making it one of the better-studied non-hormonal options. NAMS includes it as a recommended non-hormonal agent. Onset of benefit tends to be faster than with hormone therapy — often one to two weeks.
Common side effects include nausea (usually transient), dry mouth, headache, and sleep disturbance. At higher doses, blood pressure elevation can occur and warrants monitoring. Like all SNRIs, venlafaxine should be tapered rather than stopped abruptly to avoid discontinuation symptoms (dizziness, irritability, flu-like sensation). It may be particularly appropriate for people who have concurrent depression or anxiety alongside vasomotor symptoms.
How to track Venlafaxine
- Hot flash frequency before and after starting — venlafaxine's benefit typically appears within one to two weeks, so early tracking reveals whether you're responding.
- Nausea in the first one to two weeks — the most common early side effect, often dose-dependent and transient.
- Sleep quality — venlafaxine can disrupt sleep (particularly vivid dreams or insomnia) in some people, even as it reduces night sweats.
- Blood pressure readings, especially at higher doses — norepinephrine reuptake inhibition can raise blood pressure.
- Mood and anxiety — venlafaxine has antidepressant properties that may independently affect how you feel during the menopause transition.
- Log hot flash frequency daily for one to two weeks before starting and through the first four weeks — you should see separation from your baseline by week two if the drug is working.
- Rate nausea separately from other side effects during the first two weeks; it often resolves on its own and helps distinguish a temporary adjustment from a persistent tolerability problem.
- Track sleep quality as a separate dimension from night sweats — venlafaxine can affect sleep architecture independently of its vasomotor effects.
- If you are taking venlafaxine for both hot flashes and mood, log mood separately so your physician can assess both dimensions of response.
- Do not stop abruptly without tapering — log any discontinuation symptoms (dizziness, nausea, irritability) if you do taper, so the timeline is documented.
Questions to ask your physician
- My pre-treatment hot flash frequency was [X] per day. At [N] weeks on venlafaxine, my current average is [Y]. Is that response rate typical?
- I've been logging nausea at [frequency and severity] since starting. Is that expected to resolve, or does it suggest a dose adjustment?
- My sleep quality log shows [pattern] since starting — is that a typical SNRI effect, and what's the usual trajectory?
- My blood pressure readings over the past [N] weeks show [pattern]. Does that require any monitoring change at my current dose?